No Data
Tasly Pharmaceutical Group (600535.SH) plans to distribute 0.2 yuan per share for the 2024 fiscal year, with the ex-dividend date on March 26.
Tasly Pharmaceutical Group (600535.SH) announced that it intends to distribute a cash dividend of 0.20 yuan per share for the year 2024 (...
GTJA: Continuous iteration of anti-tumor therapies, domestic new drugs welcome breakthroughs.
GTJA focuses on products with significant differentiation advantages and leading companies in innovative segments.
Tasly Pharmaceutical Group Co., Ltd's (SHSE:600535) Stock Been Rising But Financials Look Weak: Should Shareholders Be Worried?
Tasly Gets China Clinical Trial Nod for Acute Ischemic Stroke Injection
Tasly Pharmaceutical Group (600535.SH): Received notification letter for drug clinical trial approval.
On March 13, Gelonghui reported that Tasly Pharmaceutical Group (600535.SH) announced that the company received the approval from the National Medical Products Administration for the clinical trial approval notice regarding allogeneic adipose mesenchymal stem cell injection (NR-20201) for the treatment of acute ischemic stroke. The NR-20201 injection is a product independently developed by the company, with the intended clinical indication being the treatment of acute ischemic stroke. Preclinical trial results indicate that the drug can synergize with vascular endothelial cells through a cell homing mechanism.
Two Sessions Time | National People's Congress Representative, Lu Qingguo from Chenguang Biotech Group: Improve the quality standards of Chinese Patent Medicine, regulate the centralized procurement model for Traditional Chinese Medicine, and optimize the
① Lu Qingguo, Director of Chenguang Biotech Group and a representative of the National People's Congress, focused on several recommendations at this year's Two Sessions, including optimizing the procurement mechanism for Traditional Chinese Medicine, enhancing the quality standards for Chinese Patent Medicine, and standardizing the Traditional Chinese Medicine granule industry; ② In addition to recommendations related to the Traditional Chinese Medicine industry, Lu Qingguo prepared several suggestions on rural social retirement insurance, rural medical insurance, and increasing support for companies sanctioned by the United States.
